Salarius Pharmaceuticals has completed its previously announced merger with Decoy Therapeutics, combining the two companies to focus on advancing Decoy's pipeline of peptide conjugate therapeutics. Following the merger and a recent underwritten public offering that raised $8 million in gross proceeds, the combined company has pro forma cash of approximately $14 million and approximately 5.9 million shares of common stock outstanding. Salarius stated that its shares continue to trade on the Nasdaq Stock Market under the ticker symbol "SLRX." The company is prioritizing the development of Decoy's lead asset, a pan-coronavirus antiviral, with plans to submit an IND application to the FDA within the next 12 months, and is also progressing other programs targeting flu, COVID-19, RSV, and gastrointestinal cancers.